Navigation Links
Transdel Pharmaceuticals Closes $4 Million Financing
Date:5/15/2008

Proceeds Will Support Phase 3 Lead Clinical Pain Program for

Ketotransdel(TM)

LA JOLLA, Calif., May 15 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP), a specialty pharmaceutical company focused on the development and commercialization of non-invasive topically administered medications, today announced the closing of a $4,000,000 private placement of its common stock and warrants.

The Company issued 1,818,180 shares of common stock at a price of $2.20 per share through a private placement to accredited investors. In addition, the investors received warrants to purchase 227,272 shares of common stock for a period of five years at a cash and cashless exercise price of $4.40 and $5.50 per share, respectively.

Proceeds from the financing will be primarily used to fund the Company's Phase 3 clinical program of Ketotransdel(TM), the Company's lead topical pain drug. Ketotransdel(TM) is a novel, topical cream-based formulation containing the non-steroidal anti-inflammatory drug ("NSAID") ketoprofen. The registration trial will be a randomized, double-blind, placebo controlled Phase 3 trial to study the efficacy and safety of Ketotransdel(TM) in acute soft tissue injuries.

Dr. Juliet Singh, President and Chief Executive Officer of Transdel Pharmaceuticals, stated, "We are very pleased to have closed this round of financing, as we plan to initiate our Phase 3 clinical study in the second quarter of this year. We are quite confident in our Phase 3 clinical study design, especially since our protocol was carefully reviewed by external experts and the U.S. Food and Drug Administration ("FDA"). We believe that Ketotransdel(TM) may address a significant unmet medical need for effective topical pain treatment without the gastrointestinal, cardiovascular and other safety concerns associated with oral pain medications."

The Company is exploring potential partnerships wit
'/>"/>

SOURCE Transdel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 31, 2014 Jeffrey T. Manuel, assistant ... Studies within the College of Arts and Sciences, is ... the history of alcohol-based fuels in Illinois. , ... have been working to build Illinois’ biofuels industry for ... aspect of the state's agricultural and business history. ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 Brady ... identification solutions, today announced a new video testimonial ... labels. In the video, a research technician at the ... it comes to labeling and storing hundreds of thousands ... has benefitted her research. , “At Brady, we design ...
(Date:10/31/2014)... ATLANTA , Oct. 31, 2014  Atlanta-based ... research efforts accompanying the onset of Ebola by ... options. Scientists at Georgia Tech,s Center for Computational ... and algorithms to find alternative uses for existing ... be able to aid the bout against Ebola. ...
(Date:10/30/2014)... London, UK (PRWEB) October 29, 2014 ... because of the world economic crisis during 2008-2009, especially ... demand has recovered and currently is keeping to a ... PVC output volume is utilized in the construction segment. ... production of pipes, profiles, tubing, sheets and rigid film. ...
Breaking Biology Technology:SIUE History Prof Manuel Working on Biofuels Book with NCERC 2SIUE History Prof Manuel Working on Biofuels Book with NCERC 3Brady Debuts New Lab Label Testimonial Video 2Atlanta-Based Intellimedix May Help Solve Ebola With Computer Algorithms 2Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 2Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 3
... Since Start of Q4 2008 , - Evaluation of strategic ... Board RoleSAN DIEGO, Jan. 5 ADVENTRX Pharmaceuticals, Inc. (NYSE ... further reduction-in-force in an effort to extend its remaining cash ... follows a reduction implemented in October 2008. In all, ...
... Jan. 5 Theodosius Dobzhansky, the late great geneticist ... makes sense except in the light of evolution."This year ... 1809) and the 150th anniversary of the publication of ... the theory of evolution by means of natural selection ...
... Requadt Promoted From PrincipalsCAMBRIDGE, Mass., and SOUTH SAN ... ("Clarus Ventures"), a leading life sciences venture capital ... M.D., Ph.D., M.P.H., to Partner and Scott Requadt, ... 2009.Dr. Cunningham joined Clarus in 2006 and represents ...
Cached Biology Technology:ADVENTRX Announces Further Cost-Cutting Measures 2ADVENTRX Announces Further Cost-Cutting Measures 3ADVENTRX Announces Further Cost-Cutting Measures 4ADVENTRX Announces Further Cost-Cutting Measures 5GEN Joins Charles Darwin 2009 Celebration 2Clarus Ventures Names Two New Partners 2Clarus Ventures Names Two New Partners 3
(Date:10/29/2014)... household and industrial products are in the environment – ... of them, scientists have yet to determine whether they ... toward doing that by estimating which substances people are ... in the ACS journal Environmental Science & Technology ... the risks to human health of any given substance ...
(Date:10/29/2014)... – As bodies decompose, their types and numbers ... they provide could mean the difference between a ... State University is using a more than $866,000 ... death-scene investigators examine these changing populations. The microbial ... location of death, gender, race, socioeconomic relations and ...
(Date:10/29/2014)... research potential of the Barcode of Life Data ... Biodiversity Data Journal (BDJ) used ... imported these into a human-readable text developed in manuscript ... were used to study the species distributions of ten ... , BOLD is originally designed to support the generation ...
Breaking Biology News(10 mins):MSU partners with Detroit to investigate death scenes 2Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2
... and technical publishing business of John Wiley & Sons, Inc. ... Taipei have signed an agreement to closely cooperate and jointly ... The journal will be available online from volume 2011 in ... collections of online resources, used by 10 million people a ...
... Drying of northern wetlands has led to much more severe ... the atmosphere, according to new research led by a University ... Nature Communications , is the first to investigate the effect ... vulnerability of that carbon to burning. "Russia, Indonesia and ...
... by Dr. Jayne S. Weiss, Professor and Chair of Ophthalmology ... found that a defect in a gene involved in a ... of invasive bladder cancer. The findings are published in the ... Cell Biology . It is the featured research of the ...
Cached Biology News:Journal of the Chinese Chemical Society expands international reach with Wiley-VCH 2Drying intensifying wildfires, carbon release ninefold, study finds 2Mutation in gene associated with rare eye disease also contributes to bladder cancer growth 2
... for maximum packaging efficiencies of T7Select vectors ... (> 109 pfu/g with control DNA) make ... at least 5 107 recombinant plaques ... from a specially designed phage that reduces ...
... delivers enhanced statistics and statistical interpretation ... improvement managers. As an accepted organizational ... simplifies statistics for novice users and ... experts. It offers a powerful JMP ...
... Mouse anti-Yersinia pestis F1 antigen, Monoclonal ... ELISA: Use at an ... an assay dependent dilution. WB: Use ... molecular weight: 18 kDa. Not tested ...
...
Biology Products: